A small titbit of information was buried within GSK’s financials this week, which threatens to bring up old news that the company would rather leave forgotten.
It relates to the China bribery scandal that rocked GSK in 2013 and for years after, as it was forced to pay hundreds of millions to settle cases with the Chinese and US governments.
In the latest twist to the saga, GSK revealed that the UK’s Serious Fraud Office (SFO) had asked for additional information on “third party advisors” that had been hired by the company during the investigation.
